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Abstract 
Purpose: To present the long-term effect of intravitreal bevacizumab (Avastin®) therapy in a 
patient suffering from retinal arterial macroaneurysm.  
Methods: Case report of a 72-year-old female diagnosed with retinal macroaneurysm in the 
superior temporal artery leading to macular edema. Functional and morphological data at 
baseline, 4 weeks, 2 months, and 13 months following treatment with two consecutive 
intravitreal bevacizumab injections are presented.  
Results: Best-corrected visual acuity improved from 20/160 at baseline to 20/20 at the 
3-months follow-up and remained stable through 13 months of follow-up. Central retinal 
thickness measured by optical coherence tomography decreased from 364 μm at baseline to 
248 μm at the 13-months follow-up. No ocular or systemic side effects were detected.  
Conclusions: Intravitreal bevacizumab therapy may lead to resolution of macular edema 
associated with retinal macroaneurysm and consequently visual improvement. This 
treatment may promise a long-lasting effect but warrant further investigation in larger 
series. 
 
Case Report 
A 72-year-old female patient with hypertension and diabetes presented with visual disturbance 
OD. Best-corrected visual acuity (BCVA) was 20/160 OD and 20/20 OS. In both eyes, anterior segment 
examination was unremarkable. Funduscopy OD showed subretinal fluid and retinal hemorrhage in 
the superior temporal arcade with associated macular edema (ME), and few small intraretinal 
hemorrhages inferior to the macula, with no ME OS (fig. 1a).  
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Based on fluorescein angiography and indocyanine green, the diagnosis of leaking retinal 
macroaneurysm OD and inactive macroaneurysm + mild nonproliferative diabetic retinopathy OS was 
confirmed (fig. 1b–e). Central retinal thickness (CRT) OD was measured by optical coherence 
tomography (OCT, SD-OCT Cirrus, Zeiss) as 364 μm (fig. 1f). 
Due to the location of the macroaneurysm OD, direct laser therapy was omitted in fear of closing 
the artery. After written consent for off-label use of intravitreal bevacizumab (Avastin®) was 
obtained, an injection (1.25 mg in 0.05 ml) was applied to the patient’s right eye. 
At 4 weeks following the injection, BCVA OD improved to 20/32. Retinal hemorrhage was reduced 
and CRT decreased to 328 μm. However, the hard exudates were more prominent. A second 
bevacizumab injection was performed 4 weeks after the first one. Four weeks after the second 
injection, the retinal hemorrhages and ME almost completely resolved (fig. 2a).Three months 
following the first injection, the ME had completely resolved, BVCA improved to 20/20 and CRT was 
242 μm. These findings remained stable after 6 and 13 months (fig. 2b) of follow-up. 
Discussion 
Acquired retinal macroaneurysms are localized fusiform or round dilatations of 
retinal arterial branches [1, 2]. Current treatment options include observation and 
direct laser coagulation [3, 4]. The use of intravitreal injection of vascular endothelial 
growth factor (VEGF) inhibitors, such as ranibizumab or bevacizumab, is an effective 
treatment modality in neovascular age-related macular degeneration [5], ME due to 
diabetes [6, 7] or vein occlusion [8]. 
Focal embolic damage to arterial walls is thought to cause retinal macroaneurysm. 
As a result, localized ischemia with VEGF-associated increased permeability and 
dilatation of the artery occurs and causes ME and hard exudates [2]. Anti-VEGF drugs 
can prevent the formation of abnormal blood vessels and counteract VEGF-induced 
vascular permeability. They might actively close the involved permeabilized retinal 
artery and normalize the vessel wall by localized inhibition of VEGF. So far, there are 
only 3 reports on retinal macroaneurysm treated with intravitreal bevacizumab [9, 10]. 
After a follow-up of 6 weeks to 8 months, BCVA increased in all patients, and no 
adverse effects were observed. 
In our patient, following the bevacizumab injection there was a reduction of ME with 
visual improvement, lasting 13 months. The therapy was well tolerated without 
adverse events. The observed beneficial effect of anti-VEGF therapy in 
macroaneurysms warrant further investigation. This treatment option should be 
considered when laser therapy is inappropriate or not working, or in patients in whom 
there is evidence of extensive ME. 
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Fig. 1. a Fundus examination of the right eye showed subretinal fluid and retinal hemorrhage in the 
superior temporal arcade with associated macular edema, and normal attached peripheral retina. In 
the left eye, few small intraretinal hemorrhages inferior to the macula, flat macula with no edema and 
normal attached peripheral retina were identified. b, c Fluorescein angiogram showing a 
hyperfluorescent spot with late leakage consisted with macroaneurysm within a larger area of 
blocked hypofluorescence OD (b) and a small retinal macroaneurysm OS (c). d, e Indocyanine green 
nicely demonstrates the superotemporal macroaneurysm OD (d) and the inferotemporal 
macroaneurysm OS (e). f Pre-treatment OCT (SD-OCT Cirrus by Zeiss) demonstrates subretinal fluids, 
originating from the macroaneurysm with associated subfoveal fluid, retinal edema and intraretinal 
lipids. CRT OD is 364 μm. 
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Fig. 2. a OCT performed 1 month following 2 IVT bevacizumab injections demonstrating normal foveal 
contour OD, complete resolution of subretinal and intraretinal fluids. Note the disappearance of the 
previously seen intraretinal lipids. b OCT performed at the last follow-up visit, 13 months following 2 
IVT bevacizumab injections demonstrating stable, normal foveal contour, and a CRT of 248 μm. 
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